Michael Chen

CO-FOUNDER and CEO, neoX Biotech

Dr. Michael Chen, Cofounder & CEO of neoX Biotech. neoX is a next-generation biotech company that combines artificial intelligence (AI) with biophysics for drug research and development, focusing on macromolecular drugs and multi-specific drugs. Dr. Chen graduated from MIT with a Ph.D. degree in physical chemistry. Dr. Chen had conducted research about computational immunology in the Institute for Medical Engineering & Science at MIT. Dr. Chen is passionate about transforming human health by frontier technologies. Dr. Chen was selected to “Outstanding Overseas Returnees-Influence Top29”, and served as the President of MIT-China Innovation and Entrepreneurship Forum.

Maya Zhang

Vice President, Head of Biology and Translational Medicine, Insilico Medicine

Dr. Man Zhang is Vice President, Head of Biology and Translational Medicine. She has more than 15 years of experience in drug discovery and translational medicine research. She has worked for domestic and Multinational Pharmaceutical Companies including Hengrui Pharmaceuticals, Johnson & Johnson, Novartis, etc. Her research cover multiple disease areas including oncology, liver fibrosis and HBV. She contributed greatly to novel target discovery and mechanism research, as well as promoting novel drug discovery programs.? ?Prior to joining Insilico, Dr. Man Zhang served as CSO, Head of discovery biology and Translational Medicine at Shanghai De Novo Pharmatech, where she led a comprehensive preclinical team covering discovery biology , translational medicine , and IND-enabling to advance multiple programs into clinical and IND-enabling studies.During her tenure at Novartis, Dr.Zhang played a critical role in delivering the first - in -class asset MAK683 currently at clinical phase 2.

Fred Mao

PARTNER and MANAGING DIRECTOR, Frost & Sullivan

Fred Mao is the Partner & Managing Director at Frost & Sullivan Greater China. He is responsible for Frost & Sullivan Greater China healthcare consulting service and capital market service business, including the industries of biotech technology, traditional pharmaceutical industry, medical device and healthcare service. Fred has affluent experiences in IPO, M&A and management consulting projects and successfully worked with many multinational companies, state-owned companies and investment communities. The clients include JW therapeutics, CARsgen, Beigene, Innovent, Wuxi Biologics, Microport, Venusmedtech, Newhorizonbio and so on.

Wei Yue

Senior Editor, FORTUNE China

Yue joined FORTUNE China in 2019. Before joining FORTUNE China, he was a Journalist for China Newsweek and Editor of China Times. In 2003, Yue graduated from Lanzhou University.